Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Xencor, Inc. - Common Stock (NQ:XNCR)

8.590 -0.330 (-3.70%)
Streaming Delayed Price Updated: 12:14 PM EDT, Apr 4, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Xencor, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
Stocks That Hit 52-Week Lows On Monday
On Monday, 524 stocks hit new 52-week lows. Areas of Interest About Today's 52-Week Lows: The largest company by market cap to set a new 52-week low was Taiwan... 
Via Benzinga
Xencor: Q4 Earnings Insights
Xencor (NASDAQ:XNCR) reported its Q4 earnings results on Wednesday, February 23, 2022 at 04:01 PM. Here's what investors need to know about the announcement. Earnings Xencor... 
Via Benzinga
Xencor Reports Fourth Quarter and Full Year 2021 Financial Results
From Xencor, Inc.
Via Business Wire
Xencor: Q3 Earnings Insights
Xencor (NASDAQ:XNCR) reported its Q3 earnings results on Monday, November 8, 2021 at 04:01 PM. Here's what investors need to know about the announcement. Earnings Xencor their... 
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
On Friday, 368 stocks hit new 52-week lows. Interesting Points From Today's 52-Week Lows: The largest company by market cap to set a new 52-week low was... 
Via Benzinga
Xencor to Report Fourth Quarter and Full Year 2021 Financial Results and Host Conference Call on February 23, 2022
From Xencor, Inc.
Via Business Wire
Earnings Scheduled For February 23, 2022
Companies Reporting Before The Bell • Sapiens Intl Corp (NASDAQ:SPNS) is likely to report earnings for its fourth quarter. • Plymouth Industrial REIT (NYSE:PLYM)... 
Via Benzinga
Xencor to Present at Upcoming Investor Conferences
From Xencor, Inc.
Via Business Wire
Xencor Highlights 2022 Corporate Priorities and Portfolio Milestones
From Xencor, Inc.
Via Business Wire
Xencor to Present at the H.C. Wainwright Bioconnect Virtual Conference
From Xencor, Inc.
Via Business Wire
Xencor Presents Data from Phase 1 Study of Plamotamab in B-cell Non-Hodgkin Lymphomas at the ASH Annual Meeting
From Xencor, Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For December 15, 2021
Upgrades B of A Securities upgraded the previous rating for ONE Gas Inc (NYSE: 
Via Benzinga
Week In Review: Shanghai's Zenas Acquires CD19 Antibody From Xenco In $480 Million Deal
In a $480 million deal, Zenas acquired global rights to a bifunctional antibody from Xencor that targets CD19. Instead of an upfront payment, Zenas will issue a warrant granting Xencor the right to... 
Via Talk Markets
Pfizer Sues Former Employee For Stealing Confidential Info On Its Megablockbuster COVID-19 Vaccine
Pfizer Inc (NYSE: PFE) has sued its former associate director of clinical statistics in a California court to get a handle on allegedly stolen information. The Company's... 
Via Benzinga
Topics Lawsuit
Exposures COVID-19 Financial Legal
Xencor Outlicenses Autoimmune Disease Candidate To Zenas BioPharma
Zenas BioPharma has acquired from Xencor Inc (NASDAQ: XNCR) exclusive worldwide rights to develop, manufacture, and commercialize obexelimab. Obexelimab is a... 
Via Benzinga
Zenas BioPharma Acquires Exclusive Worldwide Rights to Obexelimab from Xencor
From Xencor, Inc.
Via Business Wire
Xencor to Present at Upcoming Investor Conferences
From Xencor, Inc.
Via Business Wire
Xencor Presents Updated Data from the Phase 1 Study of Vudalimab, PD-1 x CTLA-4 Bispecific Antibody, at the SITC Annual Meeting
From Xencor, Inc.
Via Business Wire
Xencor Presents Data from Multiple Preclinical XmAb® Bispecific Antibody Programs and IL-12 Cytokine, XmAb662, at the SITC Annual Meeting
From Xencor, Inc.
Via Business Wire
Novartis Dumps Another Bispecific Candidate From Xencor Deal
Novartis AG (NYSE: NVS) terminated its ex-US rights to the program dubbed vibecotamab, a bispecific targeting CD123 and CD3 for acute myeloid leukemia. The... 
Via Benzinga
Xencor, inc (XNCR) Q3 2021 Earnings Call Transcript
XNCR earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Xencor Reports Third Quarter 2021 Financial Results and Announces Encouraging Preliminary Data from Ongoing Phase 1 Study of Potency-reduced IL15-Fc Cytokine, XmAb306
From Xencor, Inc.
Via Business Wire
Preview: Xencor's Earnings
Xencor (NASDAQ:XNCR) is set to give its latest quarterly earnings report on Monday, 2021-11-08. Here's what investors need to know before the announcement. Analysts estimate that... 
Via Benzinga
Xencor to Present Data from the Phase 1 Study of Plamotamab in B-Cell Malignancies at the American Society of Hematology Annual Meeting
From Xencor, Inc.
Via Business Wire
Earnings Scheduled For November 8, 2021
Companies Reporting Before The Bell • Privia Health Group (NASDAQ:PRVA) is projected to report quarterly loss at $0.11 per share on revenue of $215.14 million. •... 
Via Benzinga
Xencor Presents Clinical Data from the Phase 1 Study of Tidutamab in Neuroendocrine Tumors at NANETS’ Multidisciplinary NET Medical Virtual Symposium
From Xencor, Inc.
Via Business Wire
Xencor to Present at Upcoming Investor Conferences
From Xencor, Inc.
Via Business Wire
Xencor to Host Third Quarter 2021 Financial Results Webcast and Conference Call on November 8, 2021
From Xencor, Inc.
Via Business Wire
JNJ, Xencor Sign $1.3B Licensing Deal For B-Cell Malignancies-Targeted Bispecific Antibody
Johnson & Johnson's (NYSE: JNJ) Janssen unit has inked a licensing deal worth $100 million in upfront cash and $25 million in equity for global... 
Via Benzinga
Xencor Enters Global Collaboration and License Agreement With Janssen to Advance Plamotamab and XmAb CD28 Bispecific Antibody Combinations for the Treatment of Patients With B-Cell Malignancies
From Xencor, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS